Related references
Note: Only part of the references are listed.PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
Lomon So et al.
BIOCHEMICAL JOURNAL (2012)
Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia
Alex Paterson et al.
BLOOD (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
Andreas Agathangelidis et al.
BLOOD (2012)
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
Christine Le Roy et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Colby M. Chapman et al.
CLINICAL CANCER RESEARCH (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
J. Hoellenriegel et al.
LEUKEMIA (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
Sarah E. M. Herman et al.
BLOOD (2011)
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Davide Bagnara et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals
Alison M. McCaig et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response
Asher Chanan-Khan et al.
CANCER (2011)
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Philip C. Amrein et al.
CLINICAL CANCER RESEARCH (2011)
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation
G. V. Baracho et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia
X. Zhang et al.
LEUKEMIA (2011)
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1
Yair Herishanu et al.
LEUKEMIA & LYMPHOMA (2011)
Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
Jan A. Burger
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
Mirza Suljagic et al.
BLOOD (2010)
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
Maike Buchner et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
Faruk Ramadani et al.
SCIENCE SIGNALING (2010)
The SYK tyrosine kinase: a crucial player in diverse biological functions
Attila Mocsai et al.
NATURE REVIEWS IMMUNOLOGY (2010)
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
Jan A. Burger et al.
BLOOD (2009)
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
Ryan M. Young et al.
BLOOD (2009)
Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Matthias Niedermeier et al.
BLOOD (2009)
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P. Quiroga et al.
BLOOD (2009)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Expression and function of toll like receptors in chronic lymphocytic leukaemia cells
Marta Muzio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
Lakshmi Srinivasan et al.
CELL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation
Silvia Deaglio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
S. Gobessi et al.
LEUKEMIA (2009)
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Mohammad Luqman et al.
BLOOD (2008)
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Pablo G. Longo et al.
BLOOD (2008)
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
Charles C. Chu et al.
BLOOD (2008)
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Marta Muzio et al.
BLOOD (2008)
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Laura Z. Rassenti et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation
P. Ghia et al.
JOURNAL OF INTERNAL MEDICINE (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status
C. Ian Mockridge et al.
BLOOD (2007)
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells
Stefania Gobessi et al.
BLOOD (2007)
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway
Tomoyuki Endo et al.
BLOOD (2007)
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
William G. Wierda et al.
BLOOD (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
ZAP-70 directly enhances TgM signaling in chronic lymphocytic leukemia
LG Chen et al.
BLOOD (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
BT Messmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
B cell antigen receptor signaling 101
JM Dal Porto et al.
MOLECULAR IMMUNOLOGY (2004)
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia
G Tobin et al.
BLOOD (2004)
Survival of leukemic B cells promoted by engagement of the antigen receptor
A Bernal et al.
BLOOD (2001)
Share Paper
